These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2870236)

  • 1. Tamoxifen and non-malignant indications.
    Diver JM; Jackson IM; Fitzgerald JD
    Lancet; 1986 Mar; 1(8483):733. PubMed ID: 2870236
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical adverse effects of chemoprevention: the example of tamoxifen].
    Sasco AJ; Ah-Song R; Saez S; Kuttenn F
    Bull Cancer; 1995 Jul; 82 Suppl 3():186s-206s. PubMed ID: 7492833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Italian Tamoxifen Prevention Trial.
    Bonanni B; Veronesi U
    Dis Markers; 1999 Oct; 15(1-3):199-200. PubMed ID: 10644176
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 5. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
    Duggan C; Marriott K; Edwards R; Cuzick J
    J Clin Oncol; 2003 Oct; 21(19):3588-93. PubMed ID: 14512389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemoprevention.
    Isaacs C
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):913-4. PubMed ID: 16555431
    [No Abstract]   [Full Text] [Related]  

  • 8. [How I manage patients developing thromboembolic complications as a result of breast cancer treatment with tamoxifen ].
    Pelerin D; Silvestre RM; Jérusalem G; Sautois B; Polus M; Fillet G
    Rev Med Liege; 2002 Dec; 57(12):755-6. PubMed ID: 12632830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations.
    Jordan VC
    Cancer Invest; 1988; 6(5):589-95. PubMed ID: 3063338
    [No Abstract]   [Full Text] [Related]  

  • 10. [The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
    Savarese A
    Suppl Tumori; 2004; 3(4):S23-4. PubMed ID: 15206204
    [No Abstract]   [Full Text] [Related]  

  • 11. [The unknown of tamoxifen].
    Mignotte H
    Bull Cancer; 1995 Jan; 82(1):6-7. PubMed ID: 7742618
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen trial in healthy women at risk of breast cancer.
    Goodare H
    Lancet; 1993 Aug; 342(8868):444. PubMed ID: 8101952
    [No Abstract]   [Full Text] [Related]  

  • 14. Breast cancer and duration of tamoxifen.
    Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prophylactic use of tamoxifen: is it safe?
    Williams GM; Iatropoulos MJ; Hard GC
    Eur J Cancer Prev; 1992 Aug; 1(5):386-7. PubMed ID: 1463993
    [No Abstract]   [Full Text] [Related]  

  • 16. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
    Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
    Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
    Nelson HD; Smith ME; Griffin JC; Fu R
    Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
    Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
    Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and benign breast problems.
    Fentiman IS; Powles TJ
    Lancet; 1987 Nov; 2(8567):1070-2. PubMed ID: 2889976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials.
    Jordan VC
    Prog Clin Biol Res; 1988; 262():105-23. PubMed ID: 3287387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.